Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab Long-term Access Programme for EGPA
NCT03298061Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2015
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by GSK. Primary endpoint: Number of Participants With Adverse Events and Serious Adverse Events. Started Apr 2015; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NCT03298061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298061.